Concepedia

Sally Bowditch

SB

Statistics

Publications

4

Citations

242

H-Index

4

Active since

2017

Affiliations

Astellas Pharma (Netherlands)(Current)

Astellas Pharma (United Kingdom)

University of Alberta

Creativ-Ceutical (France)

Manchester Metropolitan University

Sally Bowditch is an author at Astellas Pharma (Netherlands) specializing in pharmacy, pharmacotherapy, and antimuscarinic drugs.

Publications per year

2017–2023

4

Publications

4

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice

Christopher R. Chapple, Jameel Nazir, Zalmaï Hakimi et al. · European Urology · 2017 · 202 citations · Full text

, , +17

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

Marcus J. Drake, Sally Bowditch, Emilio Arbe et al. · BMC Urology · 2017 · 16 citations · Full text

, , +16

Caregivers’ Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study

J.D. Marshall, Hanna Skrobanski, Lisa Moore-Ramdin et al. · Journal of Child Neurology · 2023 · 13 citations · Full text

, , +13

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK

Jameel Nazir, Malin Berling, Charles McCrea et al. · PharmacoEconomics - Open · 2017 · 11 citations · Full text

, , +17

1–4 of 4